BioAtla (BCAB) and Context Therapeutics (CNTX) announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla’s Nectin-4 x CD3 TCE. Context will assume and fund all development and commercialization activities. Under the terms of the agreement, BioAtla is eligible to receive up to $133.5 million in aggregate payments, including $15.0 million in upfront and near-term milestones with additional potential clinical, development and commercial milestones totaling $118.5 million, as well as tiered royalties on net sales.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla presented poster of Phase 2 trial data at ESMO meeting
- BioAtla rallies after Burry’s Scion discloses new stake
- BioAtla management to meet virtually with BTIG
- These 2 “Strong Buy” Penny Stocks Are Poised for a Big Rally, Say Analysts
- BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day